US 12,263,141 B2
Methods for treating cancer
Gary Hattersley, Stow, MA (US)
Assigned to RADIUS PHARMACEUTICALS, INC., Boston, MA (US)
Filed by Radius Pharmaceuticals, Inc., Boston, MA (US)
Filed on Oct. 25, 2021, as Appl. No. 17/510,050.
Application 17/510,050 is a continuation of application No. 16/545,859, filed on Aug. 20, 2019, abandoned.
Application 16/545,859 is a continuation of application No. 15/794,910, filed on Oct. 26, 2017, abandoned.
Application 15/794,910 is a continuation of application No. PCT/US2016/030316, filed on Apr. 29, 2016.
Claims priority of provisional application 62/323,572, filed on Apr. 15, 2016.
Claims priority of provisional application 62/323,576, filed on Apr. 15, 2016.
Claims priority of provisional application 62/265,663, filed on Dec. 10, 2015.
Claims priority of provisional application 62/265,658, filed on Dec. 10, 2015.
Claims priority of provisional application 62/265,696, filed on Dec. 10, 2015.
Claims priority of provisional application 62/265,774, filed on Dec. 10, 2015.
Claims priority of provisional application 62/252,916, filed on Nov. 9, 2015.
Claims priority of provisional application 62/252,085, filed on Nov. 6, 2015.
Claims priority of provisional application 62/192,940, filed on Jul. 15, 2015.
Claims priority of provisional application 62/192,944, filed on Jul. 15, 2015.
Claims priority of provisional application 62/158,469, filed on May 7, 2015.
Claims priority of provisional application 62/155,451, filed on Apr. 30, 2015.
Claims priority of provisional application 62/154,699, filed on Apr. 29, 2015.
Prior Publication US 2022/0110890 A1, Apr. 14, 2022
Int. Cl. A61K 31/137 (2006.01); A61K 31/436 (2006.01); A61K 31/519 (2006.01); A61K 31/675 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01)
CPC A61K 31/137 (2013.01) [A61K 31/436 (2013.01); A61K 31/519 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); A61K 2300/00 (2013.01)] 14 Claims
 
1. A method of treating breast cancer in a subject having an estrogen receptor alpha-positive cancer that has a Y537S mutant estrogen receptor alpha comprising administering to said subject a therapeutically effective amount of a combination of an m-TOR inhibitor selected from the group consisting of sirolimus, temsirolimus, everolimus, and ridafarolimus, and RAD1901 having the structure:

OG Complex Work Unit Chemistry
or a salt or solvate thereof.